(R)-Methyl 4-benzylmorpholine-3-carboxylate, 95.0%, 5g

2,4,6-Trimethoxy-1,3,5-triazine, 95.0%, 500g

(2R,4R)-Boc-4-phenyl-pyrrolidine-2-carboxylic acid, 99.0%, 100mg

6-bromo-1-methyl-1H-indole-2-carboxylic acid, 95.0%, 10g

5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 95.0%, 1g

Ethyl 2-chloro-6-(trifluoromethyl)isonicotinate, 95%, 100mg

trans-4-[[[[(9H-Fluoren-9-yl)methoxy]carbonyl]amino]methyl]cyclohexanecarboxylic Acid>98.0%(HPLC)(T)5g

(trans,trans)-4-((E)-Prop-1-en-1-yl)-4'-propyl-1,1'-bi(cyclohexane), 95.0%, 100g

iScope IS.1152-PLPHi Biocular with Plan phase IOS objectives and Rackless cross table (infinity)

3-Isoxazolecarboxylic acid, methyl ester, 95+%, 250mg

2-(Difluoromethyl)quinoline, 97%, 10g

2-BOC-6-OXO-2-AZASPIRO[3.4]OCTANE, 95.0%, 5g

6-BROMO-2-CHLORO-1-METHYL-1H-BENZO[D]IMIDAZOLE, 95.0%, 1g